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Abstract 55 
Dietary nitrate has been shown to increase nitrate/nitrite levels and decrease blood 56 
pressure (BP) in multiple populations. There are few reports among hypertensives and 57 
these reports have provided conflicting evidence. We aimed to assess the effect of 58 
daily nitrate compared to placebo in subjects with uncontrolled hypertension.   59 
 60 
On day 0, hypertensives wore an ambulatory BP monitor (ABPM) for 24h and blood 61 
was taken. Subjects were then randomized to 7d nitrate-rich beetroot juice (12.9mmol 62 
nitrate) followed by 7d nitrate-depleted beetroot juice (0.5mmol nitrate) or vice versa. 63 
ABPM and blood was assessed before and after both conditions.  64 
 65 
20 subjects with treated yet uncontrolled hypertension entered and completed the trial 66 
(mean age = 62.5y, mean BMI = 30.7kg/m2). Baseline BP was 137/80 ± 7/7mmHg. 67 
Dietary nitrate was well tolerated and resulted in significantly increased plasma nitrite 68 
(p=0.0004) and decreased 24h SBP and DBP compared to placebo (-8mmHg; p 69 
=0.012 and -4mmHg; p=0.018 respectively). 70 
 71 
Our results support the existing data suggesting an anti-hypertensive effect of dietary 72 
nitrate in treated yet uncontrolled hypertensives. Targeted dietary strategies appear 73 
promising contributors to BP control.  74 
 75 
 76 
 77 
 78 
 79 
 4 
Hypertension (HTN) affects >one billion people. Despite advances, blood pressure 80 
(BP) remains uncontrolled in ~50% of individuals treated with medication(1,2).  There 81 
is a need for novel, effective therapies for primary and secondary prevention of HTN.  82 
 83 
Nitric oxide (NO) is a major vasodilating molecule and plays a critical role in vascular 84 
homeostasis and BP regulation(3). Reduced NO bioavailability, either through 85 
decreased production or increased consumption, has been associated with endothelial 86 
dysfunction and implicated in the development of prehypertension(4) and HTN(5). 87 
Multiple studies have demonstrated that plasma and/or urinary NO metabolites are 88 
significantly lower in hypertensives compared to matched controls(6-11). Additionally, 89 
NO levels correlate positively with vascular function(11) and peak brachial artery 90 
dilation(12), but negatively with BP(7,9). Thus, the restoration of NO signalling provides 91 
an attractive mechanism to control HTN.  92 
 93 
Dietary nitrate has been suggested to be an important contributor to NO signalling in 94 
humans, with the first human report of an anti-hypertensive effect in 2006. A 3d double-95 
blind, crossover study of 0.1mmol/kg per day sodium nitrate resulted in a significant 96 
3.7mmHg reduction in diastolic BP in young, healthy volunteers(13). A 2008 study 97 
demonstrated marked hypotensive effect of nitrate-rich beetroot juice, (-10.4/8mmHg) 98 
which correlated with increased plasma nitrite(14). 99 
 100 
Since then, research regarding dietary nitrate and CVD has increased. Indeed, several 101 
reviews have detailed the existing pre-clinical/clinical evidence as well as possible 102 
mechanisms for dietary nitrate and its potential role in BP regulation(15-19). A 2013 103 
systematic review and meta-analysis concluded that dietary nitrate can reduce systolic 104 
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BP by 4.4mmHg (p < 0.001) and diastolic BP by 1.1mmHg (p = 0.06)(16). This and 105 
another review(17) noted that inverse associations between nitrate dose of SBP reduction 106 
(r2=0.45; p=0.033). However, it is important to note that these reviews focused mostly 107 
on normotensive, healthy, normal-weight males in acute interventions and there is a 108 
lack of data regarding hypertensives. 109 
 110 
Nonetheless, high habitual intake of dietary nitrate has been inversely associated with 111 
HTN risk(20,21). Further, a proof of principal study in 15 untreated, grade 1 hypertensives 112 
demonstrated that a single nitrate dose (3.5mmol as beetroot juice), increased plasma 113 
nitrite by 150% and decreased 24h BP (-11.2/-9.6mmHg; p<0.001) as well as arterial 114 
stiffness compared to control (p<0.05)(22). In a subsequent unblinded and uncontrolled, 115 
pilot study, we demonstrated that 14d dietary nitrate could increase serum NO in 116 
controlled and uncontrolled hypertensives but selectively lowered BP and arterial 117 
stiffness in uncontrolled hypertensives only(22). However, recent RCTs of dietary nitrate 118 
in hypertensives provided inconsistent results. One of these RCTs demonstrated that 119 
4w of 6.45mmol dietary nitrate significantly reduced BP23) However, a subsequent 120 
crossover RCT reported no effect of one week of the same nitrate dose(24). 121 
 122 
Considering these inconsistencies, we wanted to follow on from our pilot study and 123 
assess, in a more rigorous manner, the effect of 7d daily dietary nitrate on ambulatory 124 
BP, serum nitrate/nitrite, lipids and renal indices among treated but uncontrolled 125 
hypertensives.  126 
 127 
 128 
Methods  129 
 6 
Trial design 130 
This was a 7d, double-blind, randomized, placebo-controlled, crossover trial to assess 131 
the effect of dietary nitrate. Subjects were tested on three separate occasions, baseline 132 
(day 1), midpoint, (day 8) and endpoint (day 15) – before and after each intervention 133 
period (Figure 1). 134 
 135 
Study Participants 136 
Subjects with known or suspected uncontrolled hypertension, established on diverse 137 
antihypertensive regimens, were recruited from specialist clinics and invited to wear an 138 
ABPM for 24h. We excluded subjects with controlled hypertension (<130/80mmHg) 139 
as well as those with kidney disease, diabetes, cognitive impairment, or sleep apnoea 140 
and those taking organic nitrates. The study was carried out in accordance with the 141 
principles of the Declaration of Helsinki and was approved by the Research Ethics 142 
Committee of Connolly Hospital, Dublin, Ireland. 143 
 144 
Intervention 145 
This trial utilized nitrate-rich beetroot juice (NO3-) and nitrate-depleted beetroot juice 146 
(placebo; PL) as previously described(26). Independent testing and analysis of the NO3- 147 
and PL were conducted previously(26) and the specific compositions are displayed in 148 
table 1.  149 
 150 
A physician not involved in data gathering (LC) generated the allocation sequence, 151 
while a nutrition researcher enrolled subjects (CPK). After baseline assessments, 152 
subjects were randomized to consume 140ml NO3 (12.9mmol nitrate) at ~9am each 153 
 7 
morning for 7d followed by PL (0.5mmol nitrate) for 7d or the crossover condition. We 154 
selected this dose as the nitrate content is attainable with a diet rich in vegetables(27). 155 
 156 
During the trial, all subjects were provided with written and verbal instructions not to 157 
alter behaviours which are known to influence NO kinetics, including dietary, 158 
tobacco, alcohol, exercise or medication habits and not to use mouthwash or 159 
antibiotics, which are known inhibitors of dietary nitrate reduction to nitrite.  160 
Subjects took their 7th and final dose of each beverage 2-3h before their midpoint and 161 
endpoint assessments. In this manner, the juice was most active during waking hours 162 
and testing coincided with peak physiological and biochemical effect(23,28). Compliance 163 
with the juice was assessed with a daily diary. 164 
 165 
Outcome measures  166 
On all 3 testing days (days 1, 8 and 15) in an identical manner and at the same time of 167 
day, non-fasting blood was drawn and subjects were fitted with an ambulatory BP 168 
monitor for 24h as previously described(22). 169 
 170 
Lifestyle assessment 171 
Weekly dietary nitrate intake was estimated at each time-point using the ‘Nitrate Veg 172 
Table’(29). This table asks subjects to report how many times in the previous week they 173 
consumed foods rich in nitrate and provides a composite score for weekly nitrate intake. 174 
At each time-point, we also asked detailed questions regarding the subjects exercise, 175 
alcohol, medication, tobacco and alcohol habits.   176 
 177 
Biochemical analysis 178 
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On testing days, venous blood samples were drawn into serum and plasma tubes 179 
which have a low nitrate/nitrite content before ABPM set up. Serum was analysed 180 
locally for routine lipid (total cholesterol, LDL, HDL) and renal (sodium, potassium, 181 
creatinine) parameters.  182 
 183 
The half-life of NO is <1 second(30). Therefore, direct determination of NO in vivo is 184 
difficult. However, measurement of NO metabolites (nitrate/nitrite) in biological 185 
fluids reflects NO bioavailability(31). Therefore, the plasma tube was centrifuged at 186 
4,000RPM and 4°C for 10m immediately after phlebotomy. Plasma was subsequently 187 
immediately extracted into Eppendorf cry vials, frozen at −80°C and later analysed 188 
for nitrate/nitrite with the current gold standard, ozone-based chemiluminescence 189 
analysis (NO analyser, NOA280i, Sievers) which is the most accurate and sensitive 190 
NO metabolite detection method as previously described(32). 191 
 192 
Statistical methods 193 
The primary outcome was 24h SBP. Our sample size was based on the primary outcome 194 
of mean 24h ambulatory BP. At α= 0.05, we estimated that 19 participants would 195 
provide 80% power, assuming an SD of 3.8mmHg, to detect a 2.6mmHg difference in 196 
the mean 24h ambulatory BP based on our pilot study(23). 197 
 198 
The difference between baseline and post-interventions was calculated for all 199 
variables, denoted as ΔNO3- and ΔPL. Ambulatory blood pressures were analyzed by 200 
using mixed models in SAS 9.0 software by using the PROC MIXED command (SAS 201 
Institute Inc.). The subject was included as a random factor in each model. Fixed 202 
effects included the treatment (active or placebo) and the order of treatments to 203 
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account for a possible "carry over" effectThe statistical difference between ΔNO3- and 204 
ΔPL for other outcome variables was calculated using paired t-tests. Results were 205 
expressed as mean ± standard deviation. All statistical tests were conducted at the 206 
two-sided 0.05 significance level. 207 
 208 
 209 
 210 
 211 
 212 
 213 
 214 
 215 
 216 
 217 
 218 
 219 
 220 
 221 
 222 
 223 
 224 
 225 
 226 
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Results 228 
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Study population 229 
Of 93 subjects screened, 20 were recruited. There were no dropouts. Baseline 230 
characteristics are displayed in table 2. The cohort were mainly male (65%), Caucasian 231 
(90%), obese (mean BMI = 30kg/m2) and most had history of CVD.  All subjects were 232 
prescribed ≥1 antihypertensive medication. There were no reported adverse events. The 233 
juices were well tolerated and as reported previously(14,23,28), 14 subjects (70%) reported 234 
transient, red/pink urine (beetruria).  235 
 236 
Lifestyle results  237 
Throughout the trial, there was no reported change in prescribed medication, or habitual 238 
tobacco/alcohol/exercise habits between visits. Dietary nitrate intakes were constant on 239 
both a group and individual level at all 3 time-points (12.2 nitrate ‘units’ weekly. 240 
 241 
Biochemical results 242 
Plasma nitrite levels increased significantly after NO3- (p=0.001) but not after PL 243 
(p=0.3) (table 3). There was no difference at any stage between lipid, or renal 244 
parameters (data not shown). 245 
 246 
Ambulatory blood pressure results  247 
Average ABPM wear time was similar at all 3 time-points with an average of >30 248 
successful readings taken. Mean group values for 24h, day and night systolic and 249 
diastolic BP decreased after NO3- (table 3). There was no observed treatment effect 250 
regarding either SBP or DBP (24h, day or night). 251 
 252 
Discussion 253 
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Daily dietary nitrate for 7d was well tolerated and led to increased NO metabolites and 254 
reduced 24h and day BP. Our trial extends the growing literature regarding the 255 
hypotensive effect of dietary nitrate since we recruited highly selected individuals with 256 
uncontrolled hypertension but already established on anti-hypertensive medication. 257 
Further, we controlled for factors influencing NO, including diet, alcohol, smoking, 258 
exercise and medication.    259 
 260 
We observed significant increases in plasma nitrite, which were greater here (126 to 261 
732μM) than in our pilot study (100 to 175μM)(23). This can be explained by the timing 262 
of phlebotomy. Here, non-fasting blood samples were taken 2-3h after subjects 263 
consumed juice, coinciding with peak NO metabolite  bioavailability (14, 23,28). 264 
 265 
We observed significant decreases in 24h (-8/-4mmHg) and day BP (-9/-4mmHg) 266 
profiles but no significant effect at night. Considering that all subjects consumed juice 267 
2-3h before their morning clinic visit and the peak biochemical and physiological 268 
response to exogenous nitrate is reported at 2-3h(14, 23,28), the lack of effect at night is 269 
not surprising.  270 
 271 
It is noteworthy that BP values decreased after PL as well as after NO3-. It is possible 272 
that other bioactive components may affect BP. For example, antioxidants, flavonoids, 273 
anthyocianates, polyphenols, and betaine may upregulate NOS expression, decrease 274 
oxidative stress, and increase NO metabolite bioavailability.(33) These components and 275 
nitrate may have individual and synergistic additive effects, even at low doses.(33) 276 
Interestingly and importantly, if BP values hadn’t decreased after PL, the statistical 277 
significance of the antihypertensive effect of NO3- would have been even greater.  278 
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 279 
Despite the growing interest in dietary nitrate, there remains a lack of data regarding 280 
hypertensives. An acute unblinded, uncontrolled pilot study demonstrated that a single 281 
dose of dietary nitrate (3.5mmol) could increase plasma nitrite by 150% and decrease 282 
24h BP (-11.2/-9.6mmHg; p<0.001)(22). In a subsequent unblinded and uncontrolled, 283 
pilot study we demonstrated that 14d dietary nitrate increased serum NO metabolites in 284 
controlled and uncontrolled hypertensives but selectively lowered BP and arterial 285 
stiffness in uncontrolled hypertensives only(23). However, two recent, well-conducted 286 
trials provided conflicting evidence. A double-blind, randomized, controlled trial of 287 
drug-treated (n=34) and drug-naïve (n=34) hypertensives demonstrated that 28d of 288 
6.45mmol dietary nitrate significantly reduced clinic BP, home BP and 24h ABPM(24). 289 
A subsequent randomized, placebo-controlled, double-blind crossover trial assessed 27 290 
individuals with treated HTN after 7d of high-nitrate beetroot juice (6.45mmol) and 7d 291 
of nitrate-depleted beetroot juice (0.5mmol). Despite significant increases in 292 
nitrate/nitrite, there was no difference in home BP or 24h ABPM(25). 293 
 294 
It is noteworthy that we utilized double the dose of nitrate in our trial compared to these 295 
trials (12.9 vs. 6.45mmol)(24,25). We selected this dose as the nitrate content is attainable 296 
with a diet rich in vegetables(26). For example the dietary approaches to stop 297 
hypertension (DASH), traditional Japanese, Mediterranean and vegetarian diets are all 298 
high in nitrate (~10-20mmol)27,34,35. Further, the nitrate content of these diets has been 299 
suggested to mediate the major cardio-protective effects27,34,35. National dietary data 300 
surveys show average daily nitrate intakes in the USA and Europe to be 0.5 –301 
3·0mmol/d(36,37), reflecting a processed diet in low in vegetables. 302 
 303 
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The inconsistencies may be due to differing dosing regimens, intervention periods and 304 
patient demographics. The authors suggest that use of anti-hypertensives may diminish 305 
the effect of exogenous nitrate. However, half of the subjects in the Kapil et al trial(23) 306 
were on anti-hypertensives as were our subjects here and in our pilot study(22). A 307 
plausible explanation, which the authors mention(24) is that the baseline BP was quite 308 
well controlled and therefore an additional decrease is unlikely. Indeed, we observed 309 
as a similar effect in our pilot study where values in controlled hypertensives did not 310 
decrease(22). According to a recent review, dietary nitrate appears to be most 311 
hypotensive in those with higher baseline BP(38). We speculate that this may be due to 312 
crosstalk between endothelial NO synthase and the nitrate–nitrite–NO pathways, 313 
whereby beneficial effects of nitrate are likely to be more pronounced when NO 314 
synthase is compromised (e.g. HTN). Additionally, it has been demonstrated that the 315 
abundance and activity of a nitrite reductase enzyme is higher in those with higher 316 
BP(22). Other factors likely to influence the effect of dietary nitrate include habitual 317 
dietary intake, baseline NO bioavailability as well as response to exogenous nitrate. 318 
Response to exogenous nitrate is complex and determined by oral microbiota, gastric 319 
pH, and oxygen tension among others(39).  320 
 321 
Trial strengths 322 
This was a double-blind, randomized, placebo-controlled crossover trial. The use of a 323 
placebo juice means that we could fully blind and randomize this trial. The use of 324 
ABPM provides a robust measure of BP. There were no dropouts and there was no 325 
change in multiple measured factors known to influence NO kinetics throughout the 326 
trial and no participant used antibiotics or mouthwash (both known inhibitors of nitrate 327 
reduction to nitrite) during the trial. Compliance with the BRJ was 100%. 328 
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 329 
Trial limitations  330 
We included a small sample. However, considering the crossover design of our trial 331 
and the samples studied in previous nitrate studies combined with our sample size 332 
calculation, we feel that 20 well-characterized subjects can provide useful information 333 
in this context. This trial was of short duration (7d), designed to assess the efficacy and 334 
tolerability of daily dietary nitrate in uncontrolled hypertensives. We did not include a 335 
washout period as the pharmacokinetics of dietary nitrate reveal that biochemical and 336 
physiological effects of nitrate ingestion are absent after ~24h.  Therefore, subjects 337 
completed the first arm of the study on day 8 and commenced the second arm of the 338 
study on day 9.  339 
 340 
Conclusion 341 
Our results suggest that dietary nitrate has anti-hypertensive effects among 342 
uncontrolled hypertensives in conjunction with increased NO metabolites. This effect 343 
is consistent with the majority of animal model, pre-clinical and clinical data. Future 344 
studies are required to ascertain the long-term effect of dietary nitrate on BP in humans, 345 
particularly in light of evidence that dietary nitrate appears more effective in those with 346 
higher baseline BP and/or those who are treatment naïve. This intriguing concept has 347 
potential implications for multiple vulnerable populations, for example those with 348 
resistant HTN and hypertensives who refuse/can’t tolerate medication.  349 
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Table 1. Composition of nitrate-depleted and nitrate-rich beetroot juice 526 
 Nitrate-depleted beetroot 
juice 
Nitrate-rich beetroot juice  
 19 
Abbreviation PL NO3- 
Dose 140ml 140ml 
Energy (kcal)  112.42 152.46 
Carbohydrate (g) 24.64 32.186 
Sugars (g) 24.32 30.646 
Protein (g) 2.849 5.39 
Fat (g) 0.308 0.308 
SFA (g) 0.0077 0.0077 
MUFA (g) 0.0077 0.00924 
PUFA (g) 0.1386 0.1232 
Sodium (mg) 139.986 177.1 
Potassium (mg) 1041.04 1424.5 
Calcium (mg) 13.244 12.705 
Nitrate, mmol (mg) 0.19 (11.5) 12.9 (800) 
Abbreviations: MUFA = monunsaturated fatty acids; PUFA = polyunsaturated fatty acids; SFA = 527 
saturated fatty acids. 528 
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Table 2. Baseline characteristics 560 
N= 20 
Age (y) 62.5 ± 13.1 
 20 
Male gender n (%) 13 (65) 
BMI, kg/m2 (range) 30.7 ± 5.8  
 
Race n (%) 
 
Irish 18 (90) 
Asian  1 (5) 
African-American  1 (5) 
 
Smoking status (n) 
 
Current smoker 0 
Ex-smoker 8 
LLNS 12 
Years with HTN 7.5 ± 6.5  
Baseline SBP 137  ± 7  
Baseline DBP 80  ± 7  
 
Pharmacology 
 
Average No. BP meds 2 ± 1 (1 to 4) 
Aspirin n 6 
Statin n 8 
Baseline nitrate intake  (units/week) 12.2 ± 7 
 
Co-morbidities 
 
Cerebrovascular disease n 8 
CAD n 3 
Abbreviations: BMI = body mass index; CAD = coronary artery disease; HTN = hypertension; LLNS = 561 
lifelong non-smoker. 562 
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Table 3: Ambulatory blood pressure results  583 
 21 
 Baseline After PL ΔPL After NO3- ΔNO3-    Differences in                
treatment groups                                
(mmHg, 95% CI) 
*P
value
24h SBP 137 ± 7 133 ± 9 -4 129 ± 9 -8 -4.4 (-8.7 to 0.1) 0.044 
24h DBP 80 ± 7 79 ± 8 -1 76 ± 8 -4 -3.2 (-6.1 to -0.3) 0.032 
Day SBP 141 ± 8 138 ± 10 -3 132 ± 9 -9 -5.8 (-10.4 to -1.2) 0.016 
Day DBP 83 ± 6 83 ± 9 0 79 ± 8 -4 -4.0 (-7.3 to -0.6) 0.021 
Night 
SBP 
130 ± 9 125 ± 12 -5 123 ± 11 -7 -2.1 (-8.2 to 3.9) 0.473 
Night 
DBP 
74 ± 8 71 ± 11 -3 70 ± 11 -4 -1.9 (-5.6 to  1.7) 0.284 
All BP values are as mean (mmHg) ± SD 584 
ΔPL = change in ABPM following PL compared to baseline 585 
ΔNO3- = change in ABPM following NO3-compared to baseline 586 
*P-values derived from mixed model analysis as described.  587 
Abbreviations: ABP = ambulatory blood pressure; DBP = diastolic blood pressure; PL = placebo; SBP 588 
= systolic blood pressure. 589 
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Table 4: Biochemical results  622 
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 Baseline After PL ΔPL After 
NO3- 
ΔNO3- *P-value 
Nitrite 
(μM) 
126 
± 115 
131 ± 
134 
5 732 ± 
653 
581 0.0004 
CRP 9.31 10.35 0.14 14  0.37 
Bilirubin 13.8 14.8 -1 15.9 0.13  
ALT 38.5 32.3 -6.2 35.4 -3.1 0.1 
ALP 86.6 82.5 -4.1 78.2 -8.4 0.24 
GGT 55.9 55.2 -0.7 56.3 1.4 0.45 
Total 
cholesterol 
4.6 4.67 0.7 4.57 -0.03 0.25 
LDL-C 2.5 2.54 0.4 2.34 -0.16 0.1 
HDL-C 1.4 1.47 0.7 1.51 0.11 0.37 
TAG 1.49 1.42 -0.07 1.42 -0.07 0.33 
Na+ 140 140.3 0.3 140.2 0.2 0.19 
K+ 4.7 4.9 0.2 5.1 0.4 0.24 
Creatinine 76.9 78.9 2 77.1 0.2 0.13 
Urate 331.4 323.8 -7.6 331.3 -0.1 0.26 
ΔPL = change following PL compared to baseline 623 
ΔNO3- = change following NO3-compared to baseline;  624 
*P-values derived from paired t-tests of ΔNO3- vs. ΔPL 625 
Abbreviations: ALP = Alkaline phosphatase; ALT = Alanine Aminotransferase; CRP = C reactive 626 
protein; GGT = Gamma-Glutamyl Transferase; HDL-C = high density lipoprotein; K+= potassium; 627 
LDL-C = low density lipoprotein; Na+ = sodium; NO3- = nitrate rich beetroot juice; PL = placebo; TAG 628 
= Triglycerides 629 
 630 
 631 
 632 
 633 
 634 
 635 
 636 
 637 
 638 
 639 
 640 
 641 
 642 
 643 
 644 
 645 
 646 
 647 
 648 
 649 
 650 
 651 
 652 
Figure 1: Trial design 653 
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*Assessments included 24h ABPM, blood draw and assessments of dietary nitrate 698 
intake.  699 
 700 
 701 
 702 
7 received NO3- second 13 received PL second 
7 received  
PL first 
20 Recruited  
 13 received NO3- first 
Day 1 baseline assessments * 
Randomization  
Data analysis (n=20) 
Day 8 baseline assessments * 
Day 15 baseline assessments * 
 
93 screened 54 not 
eligible 
(diabetes, 
n=31; 
organic 
nitrates, n=9, 
OSAS, 
n=14) 
 
19 refused 
consent 
 
